High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
238.39M
+7.43%
-0.395
-16.96%
250.22M
+2.56%
-0.253
-29.69%
280.12M
-0.89%
-0.082
-81.24%
Estimates Revision
The market is revising Upward the revenue expectations for Tandem Diabetes Care, Inc. (TNDM) for FY2025, with the revenue forecasts being adjusted by 0.48% over the past three months. During the same period, the stock price has changed by -9.88%.
Revenue Estimates for FY2025
Revise Upward
+0.48%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+14.43%
In Past 3 Month
Stock Price
Go Down
-9.88%
In Past 3 Month
16 Analyst Rating
0Wall Street analysts forecast TNDM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNDM is 37.79 USD with a low forecast of 18.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
6 Hold
1 Sell
Moderate Buy
0Current: 14.770
Low
18.00
Averages
37.79
High
75.00
0Current: 14.770
Low
18.00
Averages
37.79
High
75.00
Leerink
Outperform
to
NULL
downgrade
$48 -> $38
2025-07-14
Reason
Leerink
Price Target
$48 -> $38
2025-07-14
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on Tandem Diabetes to $38 from $48 and keeps an Outperform rating on the shares ahead of quarterly results. The firm is updating estimates to reflect financial statement disclosures and its updated views, and price targets of several names in the space to reflect recent changes in valuation premiums.
Citi
Joanne Wuensch
Neutral -> Sell
downgrade
$24 -> $14
2025-07-09
Reason
Citi
Joanne Wuensch
Price Target
$24 -> $14
2025-07-09
downgrade
Neutral -> Sell
Reason
Citi analyst Joanne Wuensch downgraded Tandem Diabetes to Sell from Neutral with a price target of $14, down from $24. The firm believes the impact of potential competitive bidding on pump manufacturers will be a focus for investors this quarter. Amid mounting competitive pressures, it will be difficult for Tandem shares to rally, the analyst tells investors in a research note. Citi believes the stock will remain under pressure.
Truist
Hold
initiated
$24
2025-06-17
Reason
Truist
Price Target
$24
2025-06-17
initiated
Hold
Reason
Truist initiated coverage of Tandem Diabetes with a Hold rating and $24 price target. New launches should improve Tandem's position in underpenetrated/growth Type 1 and Type 2 diabetes markets and the company can enhance its competitive positioning as Mobi and future designs eventually come to market, but the company still remains over indexed to a slower growth segment that is margin disadvantaged vs. patch, the analyst tells investors in a research note. Truist expects Tandem to grow revenues at 11% for 2024-2028, even as it loses share within growing markets.
Citi
Neutral
maintain
$20 -> $24
2025-05-22
Reason
Citi
Price Target
$20 -> $24
2025-05-22
maintain
Neutral
Reason
Mizuho
Anthony Petrone
Hold
Initiates
$20
2025-04-10
Reason
Mizuho
Anthony Petrone
Price Target
$20
2025-04-10
Initiates
Hold
Reason
Mizuho initiated coverage of Tandem Diabetes with a Neutral rating and $20 price target. The firm's neutral stance reflects both the bullish feedback from its recent physician surveys that call for ongoing insulin pump category share gains from multiple daily injections and the expectations that more conversions will go to competition over the next two years, the analyst tells investors in a research note. Regarding competitive dynamics, Mizuho's sample of doctors sees Tandem losing an incremental 100bps exiting 2025, reflective of higher patient preference for competing patch-pump versus tubed-pump form factors, the firm adds.
Morgan Stanley
Patrick Wood
Buy
to
Hold
Downgrades
$45 → $22
2025-03-05
Reason
Morgan Stanley
Patrick Wood
Price Target
$45 → $22
2025-03-05
Downgrades
Buy
to
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Tandem Diabetes Care Inc (TNDM.O) is -13.59, compared to its 5-year average forward P/E of -22.20. For a more detailed relative valuation and DCF analysis to assess Tandem Diabetes Care Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-22.20
Current PE
-13.59
Overvalued PE
276.42
Undervalued PE
-320.83
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
196.87
Current EV/EBITDA
28.93
Overvalued EV/EBITDA
480.69
Undervalued EV/EBITDA
-86.95
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
5.30
Current PS
1.00
Overvalued PS
9.09
Undervalued PS
1.51
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 1444.53% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 870.81% over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 1444.53% over the last month.
Sold
Bought
TNDM News & Events
Events Timeline
(ET)
2025-07-01
10:17:40
Wells says CBP proposal for CGMs expected, insulin pumps inclusion 'a surprise'
2025-07-01
08:52:27
Diabetes device maker shares slide after payment scheduling proposal
2025-06-24 (ET)
2025-06-24
12:14:59
Diabetes stocks rally after RFK comments on HHS campaign
Sign Up For More Events
Sign Up For More Events
News
Preview
3.5
07-15NewsfilterArtificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
Preview
4.5
07-10NASDAQ.COMStocks Settle Higher on Tech Stock Strength and Lower Bond Yields
Preview
4.5
07-10NASDAQ.COMStocks See Support as Investors Await Tariff News
Sign Up For More News
People Also Watch
FAQ
What is Tandem Diabetes Care Inc (TNDM) stock price today?
What is Tandem Diabetes Care Inc (TNDM)'s business?
What is the price predicton of TNDM Stock?
What is Tandem Diabetes Care Inc (TNDM)'s revenue for the last quarter?
What is Tandem Diabetes Care Inc (TNDM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Tandem Diabetes Care Inc (TNDM)'s fundamentals?
How many employees does Tandem Diabetes Care Inc (TNDM). have?